Jump to main content
Jump to site search

All chapters
Previous chapter Next chapter

Evaluation of Methylphenidate Permeation from Daytrana™ Patches Across Silicone and Human Epidermal Membranes

Methylphenidate (MPH) is a mild central nervous system stimulant and has been a common drug used for treating attention deficit hyperactivity disorder (ADHD) for numerous years. MPH inhibits re-uptake of dopamine into the pre-synaptic nerve by blocking the dopamine transporter, leading to an increase in dopamine within the synapse and further stimulation of the dopamine receptors on the post-synaptic nerve. In patients with ADHD this has a beneficial effect on behaviour, cognition, short-term memory, reaction time, vigilance and learning. MPH is currently available in a range of dosage forms from oral controlled or immediate release formulations through to Daytrana™ a controlled release transdermal matrix patch.

Publication details


Print publication date
06 Dec 2013
Copyright year
2014
Print ISBN
978-1-84973-398-4
PDF eISBN
978-1-84973-463-9
From the book series:
Issues in Toxicology